Archive for the ‘Lyme’ Category

Seronegative Chronic Relapsing Neuroborreliosis

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/24834661?

Seronegative Chronic Relapsing Neuroborreliosis

JUL 17, 2019 — 

The letter below was forwarded to the Tick-Borne Disease Working Group as a follow-up to the first letter sent to Auwaerter which can be viewed here: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/24825076

Lyme Bumper Stickers (Public Service Announcement)
https://www.ebay.com/itm/123659578861

WAKE UP AMERICA!

 

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov, chris.smith@mail.house.gov
Cc: (98 Undisclosed recipients)
Date: July 17, 2019 at 11:49 AM
Subject: Re: Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

To the Tick-Borne Disease Working Group,

Please see my second letter below (and attachment) to Dr. Auwaerter referencing Seronegative Chronic Relapsing Neuroborreliosis. 

-Carl Tuttle

2nd Letter to Auwaerter:

——- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Paul Auwaerter <pauwaert@jhmi.edu>
Cc: psax@bwh.harvard.edu, jli@bwh.harvard.edu, cbusky@idsociety.org, tkobaya5@jhmi.edu, jmstiglich@healio.com, infectiousdisease@healio.com
Date: July 17, 2019 at 11:41 AM
Subject: Re: Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

Lyme disease often misdiagnosed, resulting in unnecessary antibiotics
Kobayashi T, et. Open Forum Infect Dis. 2019;doi:10.1093/ofid/ofz299.

July 17, 2019

The IDSA Foundation
1300 Wilson Boulevard Suite 300
Arlington, VA 22209
Attn:  Paul Auwaerter, vice chair of the IDSA Foundation

Dear Dr. Auwaerter,

While you contemplate your response to my inquiry requesting grant money for the purpose of proficiency testing of direct detection methods for Borrelia (DNA Sequencing). I would like to point out the following 1995 case study from Stony Brook Lyme Clinic.

I understand the patient received thirteen spinal taps, multiple courses of IV and oral meds, and relapsed after each one, proven by CSF antigens and/or PCR. The only way this patient (said to be a physician) remained in remission was to keep her on open ended clarithromycin- was on it for 22 months by the time of publication.

Seronegative Chronic Relapsing Neuroborreliosis.  
https://www.ncbi.nlm.nih.gov/pubmed/7796837

Lawrence C.a · Lipton R.B.b · Lowy F.D.c · Coyle P.K.d

aDepartment of Medicine, bDepartment of Neurology, and cDivision of Infectious Diseases, Albert Einstein College of Medicine, and dDepartment of Neurology, State University of New York at Stony Brook, New York, NY., USA

Eur Neurol 1995; 35:113–117  (DOI:10.1159/000117104)

Abstract

We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.

________________________

This is not the only case where a negative antibody response was identified. In fact I have attached the following document referencing:

Seronegativity in Lyme borreliosis and Other Spirochetal Infections

https://www.dropbox.com/s/3d6m45jzlhhwalu/Seronegativity.pdf?dl=0

“If false results are to be feared, it is the false negative result which holds the greatest peril for the patient.”

Your publication in Open Forum Infectious Diseases and the Healio article is suggesting that a patient couldn’t possibly have Lyme if they don’t test positive on the outdated two-tier testing algorithm. This is misleading to the reader and the medical community.

Please see the following article regarding the difficulty in diagnosing Lyme disease:

The Staggering Cost of Lyme Disease and Other Tick-Borne Illnesses

PR Newswire July 10, 2019

https://finance.yahoo.com/news/staggering-cost-lyme-disease-other-123600606.html

According to the survey:

-45% of patients needed more than three years to obtain the proper diagnosis

-65% of patients were forced to quit a job or cut back on their hours due to their symptoms

-24% of patients saw more than ten doctors before receiving a proper diagnosis

-86% of patients suffer from long-term side effects from not having been diagnosed sooner

Researchers hope that the survey will help educate the public on the risks associated with delaying testing or relying on old testing techniques. “In our view, many patients are missed because much of the testing recommended by general practitioners is based on technology from 25 years ago,” says Dr. Shah. “Science has progressed, and we can now give patients a much more accurate diagnosis than was available years ago.”

_________________________________

Dr. Auwaerter, how many Lyme patients were turned away from your clinic and left untreated because they did not test positive through unreliable serology?

It is time to move forward and find a better approach. Please stop this nonsense.

Sincerely,

Carl Tuttle

Lyme Endemic Hudson, NH

____________________

**Comment**

One of the best quotes on abysmal serology testing:  https://madisonarealymesupportgroup.com/2017/07/09/idsa-founder-used-potent-iv-antibiotics-for-chronic-lyme/

“Setting arbitrary level of antibodies to diagnose a disease that has not been amenable to Koch’s postulates seems open to question.  By the same token, ignoring antibody results unless they meet arbitrary levels seems suspect. The vast majority of patients in this series showed some WB antibody exposure, but many did not meet the arbitrary limits set….in our present state of knowledge, the diagnosis of chronic Lyme disease is a clinical one.  Many of the patients in this series have suffered serious ‘hurts’ when they have been told that they could not have LD because their WB did not meet arbitrary limits.”  – Dr. Waisbren (RIP)

 

Symptom Resolution in Pediatric Patients With Lyme Disease

https://www.ncbi.nlm.nih.gov/pubmed/30060012/

2019 May 11;8(2):170-173. doi: 10.1093/jpids/piy067.

Symptom Resolution in Pediatric Patients With Lyme Disease.

Abstract

We performed a retrospective study to determine the time frame for symptom resolution in 78 pediatric patients hospitalized with laboratory-confirmed early-disseminated or late-stage Lyme disease. The vast majority of the patients improved promptly after receiving appropriate antibiotics. Patients with a longer duration of arthritis before the institution of therapy experienced a longer time to recovery.

________________

**Comment**

The difference between a prospective study vs a retrospective study:  https://www.statsdirect.com/help/basics/prospective.htm

Prospective:  A prospective study watches for outcomes, such as the development of a disease, during the study period and relates this to other factors such as suspected risk or protection factor(s). The study usually involves taking a cohort of subjects and watching them over a long period. 

Retrospective:  A retrospective study looks backwards and examines exposures to suspected risk or protection factors in relation to an outcome that is established at the start of the study. Most sources of error due to confounding and bias are more common in retrospective studies than in prospective studies. You should take special care to avoid sources of bias and confounding in retrospective studies.

In this retrospective study, there is going to be bias as they again use “laboratory-confirmed” testing, which is going to be that same-o-same-o CDC two-tiered serology that misses over half of all cases.  A chunk of patients are omitted right from the get go.

The “vast majority” of patients improving, again is a biased statement as a multitude were excluded from the study. And while it’s true that many improve promptly with treatment, treatment failures have existed from the beginning of time: https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/

The only redeeming statement is that those with longer duration of arthritis before treatment required a longer recovery.  Unfortunately, due to bias, so many patients are omitted, so many symptoms were not accepted, and therefore this study only regurgitates previous studies done by The Cabal:  https://madisonarealymesupportgroup.com/2017/01/13/lyme-science-owned-by-good-ol-boys/

Many scientists have been ostracized for not following the party line.

https://madisonarealymesupportgroup.com/2017/01/13/lyme-science-owned-by-good-ol-boys/

 

Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections

https://www.ncbi.nlm.nih.gov/pubmed/30536421/

2019 Jan;85(1):21-31. doi: 10.1002/ana.25389.

Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Abstract

Lyme borreliosis is the object of numerous misconceptions. In this review, we revisit the fundamental manifestations of neuroborreliosis (meningitis, cranial neuritis, and radiculoneuritis), as these have withstood the test of time. We also discuss other manifestations that are less frequent. Stroke, as a manifestation of Lyme neuroborreliosis, is considered in the context of other infections. The summary of the literature regarding clinical outcomes of neuroborreliosis leads to its controversies. We also include new information on pathogenesis and on the polymicrobial nature of tick-borne diseases. In this way, we update the review that we wrote in this journal in 1995. ANN NEUROL 2019;85:21-31.

_______________

**Comment**

The reason the “summary of the literature” has led to controversies is those studies were nearly all done by “The Cabal” whom have patents on the organism itself, test kits, and vaccines:  https://madisonarealymesupportgroup.com/2019/06/28/who-owns-the-elisa-patents/, and ConflictReport

As long as researchers continue to utilize ancient, flawed research done by those with conflicts of interest, we will continue to go no where.

I am encouraged that they admit the controversy as well as the polymicrobial nature of Lyme (more than one pathogen). This admission is more than many researchers make.  Also, please note the serious manifestations of neuroborreliosis: meningitis, cranial neuritis, radiculoneuritis, and stroke.

Please, researchers, do your own work and keep an open mind.

 

 

 

Cerebrospinal Fluid CXLC13 Indicates Disease Course in Neuroinfection: An Observational Study

https://www.ncbi.nlm.nih.gov/pubmed/30660201/

2019 Jan 19;16(1):13. doi: 10.1186/s12974-019-1405-8.

Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study

Abstract

BACKGROUND:

The chemokine CXCL13 is an intensively investigated biomarker in Lyme neuroborreliosis (LNB). Its role in other neuroinfections is increasingly recognized but less clear.

OBJECTIVE:

To determine the significance of CXCL13 in established central nervous system (CNS) infections other than LNB by matching cerebrospinal fluid (CSF) CXCL13 elevations with severity of the disease course.

METHODS:

We investigated 26 patients with bacterial (n = 10) and viral (n = 16; tick-borne encephalitis, n = 6; varicella zoster infection, n = 10) neuroinfections of whom CSF CXCL13 levels were available twice, from lumbar punctures (LP) performed at admission and follow-up. As outcome classification, we dichotomized disease courses into “uncomplicated” (meningitis, monoradiculitis) and “complicated” (signs of CNS parenchymal involvement such as encephalitis, myelitis, abscesses, or vasculitis). CXCL13 elevations above 250 pg/ml were classified as highly elevated.

RESULTS:

Eight of 26 patients (31%) with both bacterial (n = 4) and viral (n = 4) neuroinfections had a complicated disease course. All of them but only 3/18 patients (17%) with an uncomplicated disease course had CSF CXCL13 elevations > 250 pg/ml at the follow-up LP (p < 0.001). At admission, 4/8 patients (50%) with a complicated disease course and 3/18 patients (17%) with an uncomplicated disease course showed CXCL13 elevations > 250 pg/ml. All four patients with a complicated disease course but only one with an uncomplicated disease course had sustained CXCL13 elevations at follow-up. Patient groups did not differ with regard to age, time since symptom onset, LP intervals, type of infections, and anti-pathogen treatments.

CONCLUSION:

Our study revealed pronounced CXCL13 elevations in CSF of patients with severe disease courses of bacterial and viral neuroinfections. This observation indicates a role of CXCL13 in the CNS immune defense and points at an additional diagnostic value as biomarker for unresolved immune processes leading to or associated with complications.

Another Propaganda Paper By Auwaerter – More Conflicts of Interest

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/24825076?

Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

JUL 15, 2019 — 

Please see the letter below to the TBDWG announcing yet another propaganda paper published by Paul Auwaerter

——— Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov, chris.smith@mail.house.gov
Cc: (98 Undisclosed recipients)
Date: July 14, 2019 at 8:50 AM
Subject: Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

To: the Tick-Borne Disease Working Group,

Please see the letter below addressed to Dr. Paul Auwaerter who “speaks with great authority” in his recent interview with Healio.

-Carl Tuttle

Letter to Auwaerter:
——- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Paul Auwaerter <pauwaert@jhmi.edu>
Cc: psax@bwh.harvard.edu, jli@bwh.harvard.edu, cbusky@idsociety.org, tkobaya5@jhmi.edu, jmstiglich@healio.com, infectiousdisease@healio.com
Date: July 14, 2019 at 8:33 AM
Subject: Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

From the Healio article:  (July 11, 2019)

https://www.healio.com/infectious-disease/emerging-diseases/news/online/%7B07d6fa1f-bd9a-479a-981b-6a46f2ceec6d%7D/lyme-disease-often-misdiagnosed-resulting-in-unnecessary-antibiotics?utm_source=selligent&utm_medium=email&utm_campaign=infectious%20disease%20news&m_bt=1150918335004

Lyme disease often misdiagnosed, resulting in unnecessary antibiotics

Kobayashi T, et. Open Forum Infect Dis. 2019;doi:10.1093/ofid/ofz299.

“Many patients seen for infectious disease evaluation of Lyme disease usually have multiple, longer standing complaints such as fatigue and musculoskeletal pain yet have been treated with antibiotics when there is not good evidence they have an active infection,”

Disclosures: Auwaerter reports serving on a scientific advisory board for DiaSorin.

July 14, 2019

The IDSA Foundation
1300 Wilson Boulevard Suite 300
Arlington, VA 22209
Attn:  Paul Auwaerter, vice chair of the IDSA Foundation

Dear Dr. Auwaerter,

The Healio article doesn’t mention how the hard fact of “not infected” was established; do you have some revolutionary test we don’t know about yet?

I would like to call attention to the following publication coauthored by Dr. Paul Mead of the US Centers for Disease Control formally announcing that serology is wholly inadequate for the management of Lyme disease.

Direct Diagnostic Tests for Lyme Disease

Clinical Infectious Diseases, ciy614, https://doi.org/10.1093/cid/ciy614

Excerpt:

“These serologic tests cannot distinguish active infection, past infection, or reinfection. Reliable direct-detection methods for active B. burgdorferi infection have been lacking in the past but are needed and appear achievable.”

From the Tick-Borne Disease Working Group 2018 Report to Congress: (Page 40)

https://www.hhs.gov/sites/default/files/tbdwg-report-to-congress-2018.pdf

“Metagenomic sequencing of DNA/RNA and proteomics can be used to identify tick-borne pathogens in clinical samples.”

Dr. Auwaerter… I would like to suggest that part of the grant money in the “search for infectious cause of Alzheimer’s disease” be directed toward organizing a nationwide proficiency test program to find out if there are any methods already available to detect Borrelia burgdorferi, Borrelia miyamotoi, Borrelia mayonii, Borrelia lonestari, Borrelia hermsii, and Borrelia turicatae (known pathogens in the U.S.) in simulated blood or plasma samples.

I believe that Milford Molecular Diagnostics may have this capability right now so doesn’t it make sense to focus on direct detection methods as soon as possible or are we going to promote outdated serology from DiaSorin for the next decade?

A response to this inquiry is requested.

Sincerely,

Carl Tuttle

Lyme Endemic Hudson, NH

Cc: Paul E. Sax, MD, EDITOR-IN-CHIEF, Open Forum Infectious Diseases

_________________

**Comment**

Of note, Auwaerter is on the scientific advisory committee of Diasorin, a company that makes diagnostic tests for Lyme as well as EBV  https://www.diasorin.com/en/node/8937.
This is important as many Lyme/MSIDS patients have both diseases and is a conflict of interest.  https://madisonarealymesupportgroup.com/2017/04/11/diagnosed-with-ebv-had-lyme/

In 1970 DiaSorin began the development of Infectious Disease products designed for use with ELISA technology. Since 2001 it has launched a broad array of new CLIA products, with unique infectious disease assays for use on the LIAISON® systems.

All DiaSorin Infectious Disease products are registered in compliance with the European CE mark rules with commercially available assays in the US having FDA clearance.